Using a randomized , open-label , crossover design , in total , 405 insulin-naive adults with T2DM from 60 centers received basal insulin glargine in one of two device treatment sequences ( 2 weeks of pen followed by 2 weeks of vial-and-syringe , or vice versa ) .